

# Nonbenzodiazepine Sedatives

Michael Levine  
Dan Quan

## REFERENCES

1. Richey SM, Krystal AD: Pharmacological advances in the treatment of insomnia. *Curr Pharm Des* 17: 1471, 2011. [PMID: 21476952]
2. <http://www.digitalcitizensalliance.org/cac/alliance/content.aspx?page=Darknet>. (Digital Citizens Alliance: Darknet Marketplace Watch: monitoring sales of illegal drugs on the Darknet.) Accessed December 15, 2014.
3. Loane C, Politis M: Buspirone: what is it all about? *Brain Res* 1461: 111, 2012. [PMID: 22608068]
4. Pecknold JC: A risk-benefit assessment of buspirone in the treatment of anxiety disorders. *Drug Saf* 16: 118, 1997. [PMID: 9067123]
5. Tiller JW, Burrows GD, O'Sullivan BT: Buspirone overdose. *Med J Aust* 150: 54, 1989. [PMID: 2909855]
6. Catalano G, Catalano MC, Hanley PF: Seizures associated with buspirone overdose: case report and literature review. *Clin Neuropharmacol* 21: 347, 1998. [PMID: 9844791]
7. Boyer EW, Shannon M: The serotonin syndrome. *N Engl J Med* 352: 1112, 2005. [PMID: 15784664] [Erratum in: *N Engl J Med* 356: 2437, 2007]
8. Toth PP, Urtis J: Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone. *Clin Ther* 26: 1355, 2004. [PMID: 15530999]
9. Gonzalez LA, Gatch MB, Taylor CM, et al: Carisoprodol-mediated modulation of GABA<sub>A</sub> receptors: in vitro and in vivo studies. *J Pharmacol Exp Ther* 329: 827, 2009. [PMID: 19244096]
10. Bramness JG, Mørland J, Sørlid HK, et al: Carisoprodol intoxications and serotonergic features. *Clin Toxicol (Phila)* 43: 39, 2005. [PMID: 15732445]
11. Reeves RR, Burke RS, Kose S: Carisoprodol: update on abuse potential and legal status. *South Med J* 105: 619, 2012. [PMID: 23128807]
12. Ratnapalan S: Chloral hydrate sedation in children. *Clin Pediatr (Phila)* 53: 933, 2013. [PMID: 24198315]
13. Nordt SP, Rangan C, Hardmasian M, et al: Pediatric chloral hydrate poisonings and death following outpatient procedural sedation. *J Med Toxicol* 10: 219, 2014. [PMID: 24532346]
14. Laurent Y, Wallemacq P, Haufroid V, Renkin J, Liolios A, Hantson P: Electrocardiographic changes with segmental akinesia after chloral hydrate overdose. *J Emerg Med* 30: 179, 2006. [PMID: 16567255]
15. Zahedi A, Grant MH, Wong DT: Successful treatment of chloral hydrate cardiac toxicity with propranolol. *Am J Emerg Med* 17: 490, 1999. [PMID: 10496517]
16. Brennan R, Van Hout MC: Gamma-hydroxybutyrate (GHB): a scoping review of pharmacology, toxicology, motives for use, and user groups. *J Psychoactive Drugs* 46: 243, 2010. [PMID: 25052883]
17. Shbair MK, Eljabout S, Lhermitte M: Drugs involved in drug-facilitated crimes: part I: alcohol, sedative-hypnotic drugs, gamma-hydroxybutyrate and ketamine. A review. *Ann Pharm Fr* 68: 275, 2010. [PMID: 20849998]
18. Mayer G: The use of sodium oxybate to treat narcolepsy. *Expert Rev Neurother* 12: 519, 2010. [PMID: 22550980]
19. Skala K, Caputo F, Mirijello A, et al: Sodium oxybate in the treatment of alcohol dependence: from alcohol withdrawal syndrome to the alcohol relapse prevention. *Expert Opin Pharmacother* 15: 245, 2014. [PMID: 24283802]
20. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B: The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol. *Clin Toxicol (Phila)* 50: 458, 2012. [PMID: 22746383]
21. Haller C, Thai D, Jacob P, Dyer JE: GHB urine concentrations after single-dose administration in humans. *J Anal Toxicol* 30: 360, 2006. [PMID: 16872565]
22. Wong CG, Gibson KM, Snead O: From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. *Trends Pharmacol Sci* 25: 29, 2004. [PMID: 14723976]
23. Thai D, Dyer JE, Benowitz NL, Haller CA: Gamma-hydroxybutyrate and ethanol effects and interactions in humans. *J Clin Psychopharm* 26: 549, 2006. [PMID: 16974199]
24. Dietze P, Horyniak D, Agius P, et al: Effect of intubation for gamma-hydroxybutyric acid overdose on emergency department length of stay and hospital admission. *Acad Emerg Med* 21: 1226, 2014. [PMID: 25377399]
25. Zvosec DL, Smith SW, Litonjua R, Westfall RE: Physostigmine for gamma-hydroxybutyrate coma: inefficacy, adverse events, and review. *Clin Toxicol (Phila)* 45: 261, 2007. [PMID: 17453877]
26. Dyer JE, Roth B, Hyma BA: Gamma-hydroxybutyrate withdrawal syndrome. *Ann Emerg Med* 37: 147, 2001. [PMID: 11174231]
27. Al-Omary FA: Melatonin: comprehensive profile. *Profiles Drug Subst Excip Relat Methodol* 38: 159, 2013. [PMID: 23668405]
28. Ramakrishnan K, Scheid DC: Treatment options for insomnia. *Am Fam Physician* 76: 517, 2007. [PMID: 17853625]
29. Holliman BJ, Chyka PA: Problems in assessment of acute melatonin overdose. *South Med J* 90: 451, 1997. [PMID: 9114843]
30. Pandi-Perumal SR, Spence DW, Verster JC, et al: Pharmacology of insomnia with ramelteon: safety, efficacy, and clinical applications. *J Cent Nerv Syst Dis* 3: 51, 2011. [PMID: 23861638]
31. Todd CM, Forrester MB: Ramelteon ingestions reported to Texas poison centers, 2005-2009. *J Emerg Med* 43: e189, 2012. [PMID: 22281032]
32. Bonacci JM, Venci JV, Gandhi MA: Tasimelteon (Hetlioz™): a new melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder. *J Pharm Pract* August 3, 2014. [Epub ahead of print] [PMID: 25092604]
33. Laudon M, Frydman-Marom A: Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders. *Int J Mol Sci* 15: 15924, 2014. [PMID: 25207602]
34. Gunja N: The clinical and forensic toxicology of Z-drugs. *J Med Toxicol* 9: 155, 2013. [PMID: 23404347]
35. Gunja N: In the Zzz zone: the effects of Z-drugs on human performance and driving. *J Med Toxicol* 9: 163, 2013. [PMID: 23456542]
36. Stranks EK, Crowe SF: The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. *J Clin Exp Neuropsychol* 36: 691, 2014. [PMID: 24931450]
37. Terzano MG, Rossi M, Palomba V, et al: New drugs for insomnia: comparative tolerability of zopiclone, zolpidem, and zaleplon. *Drug Saf* 26: 261, 2003. [PMID: 12608888]
38. Darke S, Deady M, Duflou J: Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001-2010. *J Forensic Sci* 57: 1259, 2012. [PMID: 22444504]
39. Ebbens MM, Verster JC: Clinical evaluation of zaleplon in the treatment of insomnia. *Nat Sci Sleep* 2: 115, 2010. [PMID: 23616704]
40. Forrester MB: Eszopiclone ingestions reported to Texas poison control centers, 2005-2006. *Hum Exp Toxicol* 26: 795, 2007. [PMID: 18025051]
41. Lovett B, Watts D, Grossman M: Prolonged coma after eszopiclone overdose. *Am J Emerg Med* 25: 735.e5, 2007. [PMID: 17606111]
42. Chan TY: Zopiclone induced methemoglobinemia and hemolytic anemia. *Int J Clin Pharmacol Ther* 52: 402, 2014. [PMID: 24569128]